Table 1.
Patients’ and Tumor Characteristics
| Parameters | All patients N=80 (%) |
|---|---|
| Menopausal Status | |
| Premenopausal | 16 (20.0) |
| Postmenopausal | 64 (80.0) |
| BMI | |
| Normal | 36 (45.0) |
| Obese | 44 (55.0) |
| Disease stage | |
| I | 21 (26.25) |
| II | 26 (32.5) |
| IIIA | 33 (41.25) |
| Histopathology | |
| IDC | 75 (93.8) |
| ILC | 5 (6.2) |
| ER Status | |
| Positive | 67 (83.8) |
| Negative | 13 (16.2) |
| PR Status | |
| Positive | 51 (63.8) |
| Negative | 29 (36.2) |
| HER2 Status | |
| Positive | 17 (27.0) |
| Negative | 63 (73.0) |
| Tumor grade | |
| Low | 5 (6.25) |
| Intermediate | 49 (61.25) |
| High | 26 (32.5) |
| LVI | |
| Positive | 26 (32.5) |
| Negative | 54 ( 67.5) |
| pCR | |
| Yes | 56 (70) |
| No | 24 (30) |
| Ki-67 (%) median (IQR)* | 20.0 (5.0-48.8) |
| Relapse | |
| Yes | 14 (17.5) |
| No | 66 (82.5) |
| Mortality | |
| Yes | 7 (8.8) |
| No | 73 (91.2) |
| Survival | |
| Disease free survival (months) median | 14 (11.0 – 15.0) |
| Survival time (months) median | 35.0 (34.0-36.0) |
*IQR, interquartile range